{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:01:21Z","timestamp":1776297681821,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xfre.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:05:05Z","timestamp":1773817505000},"page":"99-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reproductive medicine care in BRCA mutation carriers: an opportunity for early intervention"],"prefix":"10.1016","volume":"7","author":[{"given":"Ecem","family":"Esencan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-627X","authenticated-orcid":false,"given":"Kara N.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xfre.2026.02.009_bib1","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.xfre.2026.02.009_bib2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for brca-related cancer: US preventive services task force recommendation statement","volume":"322","author":"Force","year":"2019","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.xfre.2026.02.009_bib3","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population frequency of germline BRCA1\/2 mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.xfre.2026.02.009_bib4","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.20.02880","article-title":"Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data","volume":"39","author":"Turan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.xfre.2026.02.009_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/humrep\/dew044","article-title":"Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations","volume":"31","author":"Phillips","year":"2016","journal-title":"Hum Reprod"},{"issue":"8030","key":"10.1016\/j.xfre.2026.02.009_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-024-07931-x","article-title":"Genetic links between ovarian ageing, cancer risk and de novo mutation rates","volume":"633","author":"Stankovic","year":"2024","journal-title":"Nature"},{"issue":"7872","key":"10.1016\/j.xfre.2026.02.009_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-021-03779-7","article-title":"Genetic insights into biological mechanisms governing human ovarian ageing","volume":"596","author":"Ruth","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.xfre.2026.02.009_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/humrep\/dex008","article-title":"Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients","volume":"32","author":"Goldman","year":"2017","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.xfre.2026.02.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmg.2006.043257","article-title":"Clinical and molecular features associated with biallelic mutations in FANCD1\/BRCA2","volume":"44","author":"Alter","year":"2007","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.xfre.2026.02.009_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2159-8290.CD-12-0421","article-title":"Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer","volume":"3","author":"Domchek","year":"2013","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.xfre.2026.02.009_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/2159-8290.CD-14-1156","article-title":"Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype","volume":"5","author":"Sawyer","year":"2015","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.xfre.2026.02.009_bib12","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jamaoncol.2022.3677","article-title":"Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis","volume":"8","author":"Marklund","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.xfre.2026.02.009_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.fertnstert.2024.03.026","article-title":"Fertility drugs and cancer: a guideline","volume":"122","year":"2024","journal-title":"Fertil Steril"},{"issue":"16","key":"10.1016\/j.xfre.2026.02.009_bib14","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2007.14.8700","article-title":"Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study","volume":"26","author":"Azim","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.xfre.2026.02.009_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/humrep\/dex027","article-title":"The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review","volume":"32","author":"Rodgers","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2026.02.009_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574669","article-title":"Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis","volume":"10","author":"Bonardi","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.xfre.2026.02.009_bib17","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.xfre.2026.02.009_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.fertnstert.2019.07.1349","article-title":"Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review","volume":"112","author":"Chen","year":"2019","journal-title":"Fertil Steril"},{"issue":"13","key":"10.1016\/j.xfre.2026.02.009_bib19","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.xfre.2026.02.009_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/GME.0000000000000126","article-title":"Hormone therapy in oophorectomized BRCA1\/2 mutation carriers","volume":"21","author":"Marchetti","year":"2014","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.xfre.2026.02.009_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334126000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334126000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:26:06Z","timestamp":1776295566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334126000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666334126000309"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2026.02.009","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reproductive medicine care in BRCA mutation carriers: an opportunity for early intervention","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}